Active, not recruitingPhase 3NCT04285086
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
Studying Essential thrombocythemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PharmaEssentia
- Principal Investigator
- Toshiaki Sato, MD/PhDPharmaEssentia Japan K.K.
- Intervention
- Ropeginterferon alfa-2b(biological)
- Enrollment
- 174 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2029
Study locations (30)
- Washington University School of Medicine - Division of Oncology, St Louis, Missouri, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- University of Utah, Salt Lake City, Utah, United States
- St. Paul's Hospital, Vancouver, British Columbia, Canada
- Princess Margaret Hospital, Toronto, Ontario, Canada
- Jewish General Hospital, Montreal, Quebec, Canada
- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
- Peking University People's Hospital, Beijing, Beijing Municipality, China
- The First Affiliated Hospital, Chongqing Medical University, Chongqing, Chongqing Municipality, China
- NanFang Hospital of Southern Medical University, Guangzhou, Guangdong, China
- Union Hospital Tongji Medical College Huazhong University of Science and Technolog, Wuhan, Hubei, China
- Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
- The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
- Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
- Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04285086 on ClinicalTrials.govOther trials for Essential thrombocythemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG
- RECRUITINGNCT07203768A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGNANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong
- RECRUITINGPHASE1NCT06343805A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc.
- RECRUITINGPHASE2NCT06541249MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialIcahn School of Medicine at Mount Sinai
- RECRUITINGPHASE2NCT06552429Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ETXiamen Amoytop Biotech Co., Ltd.